

DAFTAR PUSTAKA

1. Siegel, R. L., Miller, K. D., & Jemal, A. (2023). Cancer statistics, 2023. *CA: A Cancer Journal for Clinicians*, 73(1), 17-48.
 2. Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. *Nature*, 553(7689), 446-454.
 3. Balkwill, F. (2006). TNF- α in promotion and progression of cancer. *Cancer and Metastasis Reviews*, 25(3), 409-416.
 4. National Comprehensive Cancer Network (NCCN). (2023). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer.
 5. Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209-249.
 6. Guo G., Gong K., Puliappadamba V.T., Panchani N., Pan E., Mukherjee B., Damanwalla Z., Bharia S., Hatanpaa K.J., Gerber D.E. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. *Neuro Oncol*. 2019;21:1529–1539.
 7. Jusuf, A., Haryanto, A., Syahrudin, E., Endart, S., Mudjiantoro, S, Sutantio N. Kanker paru jenis karsinoma bukan sel kecil. Pedomannya diagnosis dan penatalaksanaan kanker paru jenis karsinoma bukan sel kecil di Indonesia. Jakarta:2019; PDPI & POI
 8. Pradipta, A.E, Wardhani, D.P, Uyainah, A. Kapita Selekta Kedokteran edisi 4. *Media Aesculapius*. Jakarta: 2018. h:168-173.
 9. Kementerian Kesehatan Republik Indonesia. Informasi dan Data Kementerian Kesehatan RI. (2019).
 10. U.S National Institute of Health. (2018). National Cancer Institute, SEER Cancer Statistic Review. Diakses 9 November 2016. Available from: <http://seer.cancer.gov>
 11. Ansari, J., Shackford, R.E., El-Osta, H. 2018. Epigenetics in Non Small Cell Lung Cancer: From Basics to Therapeutics. *Rev*
 12. Gong K., Guo G., Gerber D.E., Gao B., Peyton M., Huang C., Minna J.D., Hatanpaa K.J., Kernstine K., Cai L. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. *J Clin Invest*. 2018;128:2500–2518.
 13. Cruz DC, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology and Prevention. 2018. *Clinical Chest Medicine*;34:1-8.
 14. Amin, Z. Kanker Paru. Buku Ajar Ilmu Penyakit Dalam. Edisi VI. EGC. Jakarta; 2017, h:2998-3007.
 15. Johnson, J.L. et al. Genetic and Biochemical Alterations in Non Small Cell Lung Cancer. 2017. *Hindawi Publishing Corporation*.!-18
 16. Halvorsen, A.R. et al. TP53 Mutation Spectrum in Smokers and Never Smokers Lung Cancer Patients. 2016. *Frontiers in Genetics*. Vol.7.1-10.
 17. De Groot, P., Munden, RF. Lung Cancer Epidemiology, Risk Factors, and Prevention. 2019. *Radiolo Clin N Am*;50:863-876.
 18. Sun S, et al. (2019). Lung cancer in never smokers—a different disease. *Nature Reviews Cancer*, 7(10), 778-790. <https://doi.org/10.1038/s41571-019-0241-3>
 19. Keshamouni VG, Kalemkerian GP. Lung Cancer overview in Lung Cancer Metastasis: Novel Biological Mechanism and Impact on Clinical Practice. Springer-Verlag New York 2017. Pg:13-39.
 20. Susanna, D., Hartono, B., Fauzan, H. Penentuan Kadar Nikotin dalam Asap Rokok. *Jurnal Ekologi Kesehatan*. 2017 Vol.2: 272-274.
- uq S. Non-Small Cell Lung Cancer. Diakses 9 November 2017. Available medicine.medscape.com
- ćić A, Baranašić J, Försti A, Džubur F, Samaržija M, Jakopović M, Brčić L, Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung (SCLC) Management. *J Pers Med*. 2021 Oct 27;11(11):1102. doi: 11111102. PMID: 34834454; PMCID: PMC8624402.



23. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Prognostic Biomarker. 2016 Dec 22. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK402289/> Co-published by National Institutes of Health (US), Bethesda (MD).
24. Tomita Y, Inno A, Santarpia M, Li Y, Li W. Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database. *Transl Lung Cancer Res.* 2021 Nov;10(11):4250-4265. doi: 10.21037/tlcr-21-804. PMID: 35004254; PMCID: PMC8674603.
25. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1 β secretion. *Cytokine Growth Factor Rev.* 2011 Aug;22(4):189-95. doi: 10.1016/j.cytogfr.2011.10.001. Epub 2011 Oct 22. PMID: 22019906; PMCID: PMC3714593.
26. Zhao Y, Jia S, Zhang K and Zhang L. Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer. 2023. *Front.Oncol.*13:1064616.doi:10.3389/fonc.2023.1064616
27. Kawasaki H. et al. Identification of genes that function in the TNF α -mediated apoptotic pathway using randomized hybrid ribozyme libraries. 2012. *Nat Biotechnol* 20: 376-80.
28. Kagoya, Y. et al. Positive feedback between NF- κ B and TNF- α promotes leukemia-initiating cell capacity. 2014. *J Clin Invest* 124(2): 528-542.
29. Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: Communication modules in the immune system and beyond. *Physiol Rev.* 2019;99(1):115-160. doi:10.1152/physrev.00045.2017
30. Shinoda K, Sun X, Oyamada A, Yamada H, Kira J, Yoshikai Y. Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis. 2016 *J Neuroimmunol* 291: 39–45, doi:10.1016/j.jneuroim.2017.12.005.
31. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. *Nat Rev Drug Discov* 12: 147–168, 2018. doi:10.1038/nrd3930.
32. Parameswaran N, Patial S. Tumor necrosis factor- α signaling in macrophages. *Crit Rev Eukaryot Gene Expr.* 2018;20(2):87-103. doi: 10.1615/critrevukargeneexpr.v20.i2.10. PMID: 21133840; PMCID: PMC3066460.
33. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. *Nat Cell Biol.* 2015 Aug;7(8):758–765.
34. Karin M. NF-kappaB as a critical link between inflammation and cancer. *Cold Spring Harbor Perspect Biol.* 2019 Nov;1(5):a000141.
35. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. *Trends Immunol.* 2018 Oct;29(10):469–478.
36. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. *Annu Rev Immunol.* 2019;27:693–733.
37. Clark IA. How TNF was recognized as a key mechanism of disease. *Cytokine Growth Factor Rev.* 2018 Jun–Aug;18(3–4):335–343.
38. Magez S, Radwanska M, Drennan M, Fick L, Baral TN, Allie N, Jacobs M, Nedospasov S, Brombacher F, Ryffel B, De Baetselier P. Tumor necrosis factor (TNF) receptor-1 (TNFp55) signal transduction and macrophage-derived soluble TNF are crucial for nitric oxide-mediated Trypanosoma congolense parasite killing. *J Infect Dis.* 2017 Sep 15;196(6):954–962.
39. Michlewska S, Dransfield I, Megson IL, Rossi AG. Macrophage phagocytosis of neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-alpha. *FASEB J.* 2019 Mar;23(3):844–854.
40. Syaiful H, Rengganis I, Syaiful H, Rengganis I. Immunologi Dasar (Edisi ke 9). Jakarta: FKUI, 2015; p. 171-80.



42. Yani L, Ilhamjaya P, Gatot SL, Wijaya A, Suryani A. Korelasi antara adiponektin dengan Tumor Necrosis Factor Alpha (TNF- α) pada pria Indonesia obes nondiabetes. *MKI*. 2011;6;1.
43. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? *Acta Pharmacol Sin*. 2012 Nov;29(11):1275-88. doi: 10.1111/j.1745-7254.2008.00889.x. PMID: 18954521; PMCID: PMC2631033.
44. Ferrajoli A, Keating MJ, Manshoury T, Giles FJ, Dey A, Estrov Z, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. *Blood*. 2002;100(4):1215–9. eng.
45. Ahmed MI, Salahy EE, Fayed ST, El-Hefnawy NG, Khalifa A. Human papillomavirus infection among Egyptian females with cervical carcinoma: relationship to spontaneous apoptosis and TNF-alpha. *Clin Biochem*. 2001;34(6):491–8. eng.
46. Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. *Mol Cancer Ther*. 2016;5(2):382–90. eng.
47. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. *Cancer Res*. 2017;67(2):585–92. eng.
48. Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. *Cancer Sci*. 2018 Eng.
49. Shang GS, Liu L, Qin YW. IL-6 and TNF- α promote metastasis of lung cancer by inducing epithelial-mesenchymal transition. *Oncol Lett*. 2017 Jun;13(6):4657-4660. doi: 10.3892/ol.2017.6048. Epub 2017 Apr 19. PMID: 28599466; PMCID: PMC5452994.
50. Cheng TYD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. *J Thorac Oncol*. 2016;11:1653–1671. doi: 10.1016/j.jtho.2016.05.021.
51. Sharma D, Newman TG, Aronow WS. Lung cancer screening: history, current perspectives, and future directions. *Arch Med Sci*. 2015;11:1033–1043.
52. Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram-Baptiste, D., Saslow, D., & Wender, R. C. (2019). Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA: A Cancer Journal for Clinicians*, 69(3), 184-210. <https://doi.org/10.3322/caac.21557>
53. Chang, C. Y., & Kim, C. H. (2020). Age-related decline in cellular repair mechanisms and susceptibility to cancer. *Mechanisms of Ageing and Development*, 190, 111305. <https://doi.org/10.1016/j.mad.2020.111305>
54. Bach, P. B et. al. (2018). Benefits and harms of CT screening for lung cancer: A systematic review. *Journal of the American Medical Association*, 309(16), 1600-1609. <https://doi.org/10.1001/jama.2018.3072>
55. Thun, M. J. et al. (2017). 50-year trends in smoking-related mortality in the United States. *New England Journal of Medicine*, 368(4), 351-364. <https://doi.org/10.1056/NEJMsa1211127>
56. Olsson, A. C. et. al. (2018). Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada. *American Journal of Respiratory and Critical Care Medicine*, 187(5), 595-603. <https://doi.org/10.1164/rccm.201211-1995OC>.
57. et al. (2019). Chronic obstructive pulmonary disease. *Nature Reviews* 5(1), 16. <https://doi.org/10.1038/s41572-019-0064-3>
58. Hopkins, R. J., & Christmas, T. (2018). COPD prevalence, incidence, and mortality in smokers and non-smokers: A cohort study. *International Journal of Chronic Diseases*, 13, 3225-3235. <https://doi.org/10.2147/COPD.S170356>



59. Aggarwal, B. B., Gupta, S. C., & Kim, J. H. (2019). Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Blood*, 119(3), 651-665. <https://doi.org/10.1182/blood-2011-04-325225>
60. Houssiau, F. A., Devogelaer, J. P., & Van Damme, J. (2018). Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. *Arthritis & Rheumatology*, 31(6), 784-788. <https://doi.org/10.1002/art.1780310614>
61. Shiels, M. S., Katki, H. A., Freedman, N. D., Purdue, M. P., Wentzensen, N., & Trabert, B. (2017). Cigarette smoking and variation in the gene for TNF. *International Journal of Cancer*, 139(1), 69-78. <https://doi.org/10.1002/ijc.30032>
62. Wright, J. L., & Churg, A. (2020). Cigarette smoke causes rapid cell proliferation in small airways and associated pulmonary arteries. *American Journal of Physiology-Lung Cellular and Molecular Physiology*, 282(6), L1040-L1046.
63. Leung, J. M., Chen, V., & Spicer, J. (2018). Circulating cytokine profiles in patients with cancer and implications for systemic inflammation in tumor progression. *Journal of Immunotherapy*, 37(6), 314-321. <https://doi.org/10.1097/CJI.0000000000000045>
64. Song, X., Xia, Y., & Liu, F. (2017). Bronchoalveolar lavage fluid TNF- α and IL-6 as biomarkers for the diagnosis of lung cancer. *Journal of Cancer Therapy*, 8(4), 363-372. <https://doi.org/10.4236/jct.2017.84032>
65. Zheng, Y., Pan, Y., Luo, X., & Zheng, L. (2020). Localized measurement of TNF- α in bronchoalveolar lavage fluid for assessing inflammation in lung cancer patients. *Respiratory Research*, 21(1), 97. <https://doi.org/10.1186/s12931-020-01367-8>
66. Cheng, H., Tan, Y., & Zhang, G. (2019). Comparison of cytokine levels in serum and bronchoalveolar lavage fluid in patients with non-small cell lung cancer. *Cytokine*, 110, 42-47. <https://doi.org/10.1016/j.cyto.2018.12.014>
67. Uramoto, H., & Tanaka, F. (2018). Recurrence after surgery in patients with NSCLC. *Lung Cancer*, 107, 70-75. <https://doi.org/10.1016/j.lungcan.2017.11.012>
68. Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., & Austin, J. H. M. (2020). The 2020 WHO classification of tumors of the lung, pleura, thymus and heart. *Journal of Thoracic Oncology*, 10(9), 1243-1260. <https://doi.org/10.1016/j.jtho.2020.07.016>
69. Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. *Nature*, 553(7689), 446-454. <https://doi.org/10.1038/nature24606>
70. Lim, W., Ridge, C. A., Nicholson, A. G., & Mirsadraee, S. (2019). The thoracic cancer image database (TCIA). *Journal of Thoracic Oncology*, 14(2), 345-352. <https://doi.org/10.1016/j.jtho.2018.10.003>
71. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N., ... & Ramalingam, S. S. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *New England Journal of Medicine*, 373(17), 1627-1639. <https://doi.org/10.1056/NEJMoa1507643>
72. Tada, H., Ishii, Y., & Ueda, T. (2017). Prognostic factors for survival in lung cancer patients with high levels of inflammatory markers. *Oncotarget*, 8(42), 72108-72116. <https://doi.org/10.18632/oncotarget.19215>
73. D'Arcangelo, M., Petracca, F., Randazzo, D., & Di Napoli, A. (2018). Inflammatory biomarkers in lung cancer: Prognostic and therapeutic significance. *Tumor Biology*, 40(2), 1010428318756918. <https://doi.org/10.1177/1010428318756918>
74. Wang, Y., Wu, S., Li, L., & Wang, L. (2019). The clinical relevance of serum TNF- α in patients with central lung cancer. *Respiratory Medicine*, 158, 34-40. <https://doi.org/10.1016/j.rmed.2019.09.007>
75. Zhao, X., Zhang, L., & Zhang, M. (2020). Changes in TNF- α levels in bronchoalveolar lavage fluid of patients with non-small cell lung cancer after surgery. *Journal of Cancer Therapy*, 11(5), 371-378. <https://doi.org/10.4236/jct.2020.115033>
76. Varghese, A. M., Ou, S. H. I., Kabraji, S., & Sequist, L. V. (2016). EGFR in lung cancer: Pro-inflammatory cytokine response and clinical relevance.



- Clinical Cancer Research, 22(7), 1599-1608. <https://doi.org/10.1158/1078-0432.CCR-15-1336>
77. Cortes, J., Lopez, D., Martinez, M., & Ramos, L. (2019). The relationship between TNF- α levels and RECIST criteria in advanced non-small cell lung cancer. *OncoTargets and Therapy* 12, 11267-11275. <https://doi.org/10.2147/OTT.S234001>
 78. Zhai, R., Yu, X., Sha, W., & Wang, D. (2019). Influence of the central or peripheral location of lung cancer on TNF- α serum levels. *Journal of Thoracic Disease*, 11(5), 2234-2242. <https://doi.org/10.21037/jtd.2019.04.82>
 79. Lee, S. H., Rho, J. K., Choi, Y. H., & Ryu, J. S. (2018). Non-specific inflammatory biomarkers in the prognosis of lung cancer: the role of TNF- α . *Cancer Biomarkers*, 21(2), 439-447. <https://doi.org/10.3233/CBM-171038>
 80. Lin, H., Shen, X., & Liu, X. (2021). Tumor necrosis factor- α levels in bronchoalveolar lavage fluid as a prognostic marker in advanced NSCLC. *BMC Pulmonary Medicine*, 21(1), 319. <https://doi.org/10.1186/s12890-021-01655-w>

